Metraipolis › archive › dc_b294c8cec2d9

Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41275123
DOI
10.1186/s12885-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-08T08:15:54.416Z
SHA-256 of the archived text
b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31
Stable URL of this page
https://metraipolis.com/documento/dc_b294c8cec2d9

How to cite

Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123 — Europe PMC (en), https://europepmc.org/article/MED/41275123 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b294c8cec2d9 (Metraipolis archive dc_b294c8cec2d9, sha256 b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31)
BibTeX
@misc{dcb294c8cec2d9,
  title = {Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41275123},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b294c8cec2d9; sha256 b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41275123. Agents can read the archived copy with the MCP tool read_document.